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INTRODUCTION 
Breast cancer (BC) is the most common tumour in women, being the first cause of all deaths due to cancer. Human epidermal growth factor receptor 2 (HER2) is a strong phenotype 
determinant present in approximately 20-30% of all BCs. Specific therapy against this receptor with Trastuzumab, a humanized monoclonal antibody, decisively contributed to a prognostic 
improvement. Despite its efficacy in prolonging progression-free-survival, 70% of patients with HER2-positive BC demonstrates resistance to Trastuzumab, stressing the importance of 
developing new therapeutic strategies. Recent advances in Nanobiotechnology have led to development of nanoparticles for the diagnosis and treatment of human cancer. Aim of this work 
was to develop and validate a nanoparticles-based system for early detection and treatment of HER2 positive breast cancer lesions. Spherical silica nanoparticles (SiNPs) were engineered with 
anti-HER2 antibody fragment and functionalized with both radioactive and fluorescence probe for respectively PET/SPET and microscopy detection. In addition, the antibody-receptor 
interaction will be used to specifically target therapy by transporting treatment into cancer cells. 
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METHODS 
SiNPs of 50 nM were filled with FITC for fluorescence imaging and conjugated with the half-chain of a monoclonal antibody Trastuzumab (ETZ-2) or not (ETZ-1, control) and with nitril-triacetic 
acid (NTA). 
In vitro kinetic and toxicity: to study in vitro kinetic in breast cancer cells, ETZ-1_NTA and ETZ-2_NTA were incubated at different times (20 min, 1h, 4h, 24h) with HER2 positive (SK-BR-3) and 
negative (MDA-MB-468) human cell lines and analyzed by flow cytometry (FACS) and optical fluorescence microscopy. For cytotoxicity assessment, viability test and MTT assay were 
performed incubating SK-BR-3 (mammary adenocarcinoma, HER2 positive) and MCF-10A (non-transformed epithelial cell line derived from human fibrocystic mammary tissue, HER2 negative) 
with ETZ-1_NTA or ETZ-2_NTA for 20 min, 1h, 4h and 24h. Radiolabeling: ETZ-1 and ETZ-2 derivatized with NTA, were reacted with His-Tag, previously labeled with the 99mTc-Tricarbonyl 
complex. In vitro binding: to study in vitro kinetic uptake of radiolabeled SiNPs, 99Tc-NTA_ETZ-1 and 99Tc-NTA_ETZ-2 were incubated at different times (20 min, 1h, 4h, 24h) with SK-BR-3 and 
MDA-MB-468 breast cancer cell lines. Cells and medium were counted using a -counter and cell uptake expressed as % of total radioactivity. Ex vivo biodistribution: the same radiolabeled 
SiNPs were used for ex vivo biodistribution in an animal model of breast cancer obtained after the implantation of SK-BR-3 or MDA-MB-468 cells under the right shoulder. Animals were 
injected in a tail vein with 100-120 µCi of radiolabeled ETZ-1 or ETZ-2 and sacrificed at 4h. Tumour and peripheral organs were dissected and counted in a -counter to obtain the percentage 
of injected dose per gram of tissue (%ID/g). Subsequently, ex vivo distribution was achieved for labeled ETZ-2 and ETZ-1 also at 6h, 24h in the HER2+ model. In parallel, a tumour sample were 
also frozen in liquid N2 and sectioned into 10µm slices for fluorescence microscopy and a sample of tumour and peripheral organs were treated for proteogenomic analysis. 
 
RESULTS 
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In vitro fluorescence microscopy for non-radiolabeled SiNPs 
Figure 3. In vitro binding specificity evaluation of SiNPs in HER2 
positive and negative breast cancer cell lines by fluorescence 
microscopy.  
At 4h after incubation, we observed exclusively for ETZ-2 
nanoparticles a specific binding to SK-BR-3 (HER2+) cells, as 
showed by intracytoplasmic fluorescence, compared to the MDA-
MB-468 cells (HER2-). ETZ-1 binding resulted not specific in both 
HER2+ and HER2- cell lines. 
In vitro toxicity assay of non-radiolabeled SiNPs 
Figure 2. In vitro toxicity evaluation of SiNPs in breast cancer cell line SK-BR-3 
(HER2+) and in non-transformed mammary epithelial cell line MCF-10A (HER2-) by 
UV/VIS spectrophotometry.  
The analysis revealed no significant modification over time of succinate 
dehydrogenase activity (MTT test) in both cell lines (MCF-10A and SK-BR-3), after 
incubation with ETZ-1_NTA and ETZ-2_NTA nanoparticles. 
In vitro uptake for radiolabeled SiNPs 
Figure 4. In vitro uptake of radiolabeled SiNPs in HER2 positive and negative breast 
cancer cell lines. 
ETZ-1 nanoparticles bound in nonspecific way both to MDA-MB-468 (HER2-) and SK-BR-3 
(HER2+) cells. ETZ-2 showed a specific binding only to SK-BR-3 cells. This binding is 2,3 
times higher than that observed for MDA-MB-468 cells, after 4h of incubation. 
Ex vivo fluorescence microscopy for radiolabeled SiNPs 
Figure 6. Ex vivo binding specificity evaluation of SiNPs in HER2 
positive and negative breast cancer animal models by 
fluorescence microscopy. 
Imagines obtained from tumour slices, at 4h after injection, showed 
a great and deep signaling localization for ETZ-2 SiNPs in HER2+ (SK-
BR-3) breast cancer tissue, respect to that HER2- (MDA-MD-468).  
Preliminary results showed that 99mTc-NTA_ETZ-2 SiNPs could be a useful system for HER2 positive breast cancer detection and treatment. Proteomic and genomic characterization of tumour 
and tissues deriving from animals treated or not with SiNPS are ongoing. Next step will be the evaluation of SiNPs efficacy in the targeting of chemotherapy, by filling nanoparticles with 
doxorubicin. Treatment efficacy will be evaluated in vitro and in vivo in SK-BR-3 (HER2+) and MDA-MB-468 (HER2-) cells, in comparison with free and liposomal doxorubicin administration. 
Moreover efficacy, toxicity and safety of DOXO-SiNPs will be evaluated in vitro in MCF-10A and SK-BR-3 cell lines and in vivo by monitoring tumour growth and proteogenomic analysis. 
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In vitro uptake of non-radiolabeled SiNPs 
Figure 1. In vitro kinetic of SiNPs in HER2 positive and negative breast cancer cell 
lines by FACS analysis.  
HER2 positive cells (SK-BR-3) showed a strong increase over time of ETZ-2_NTA 
nanoparticles uptake  (right) compared to HER2 negative cells (MDA-MB-468, right). 
ETZ-1_NTA uptake followed a nonspecific trend over time, resulting at 24h higher in 
HER2- compared to HER2+ cells. 
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Ex vivo biodistribution of radiolabeled SiNPs at 4h 
Figure 5. Ex vivo biodistribution of radiolabeled SiNPs in HER2 positive and negative breast 
cancer model at 4h. 
ETZ-1 and ETZ-2 showed different kinetic of distribution in SK-BR-3 tumour and eliminating 
organs as liver and kidney. ETZ-2 uptake in tumour was maximum at 4h and decreased 
thereafter; ETZ-1 uptake increased slowly over time. Same results were obtained from 
biodistribution study performed at 4h after ETZ-2 injection in both HER2+ and HER2- models 
(data not shown). Tumour to muscle ratio of ETZ-2 nanoparticles was 3,53 in the HER2+ (SK-BR-
3) tumour at 4h p.i., while the ratio for ETZ-1resulted 1,69 in the same tumour model. 
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